ADAG News and Press, Adagene Inc. From 12/16/22

SAN DIEGO and SUZHOU, China, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced a clinical trial collaboration with Roche to evaluate the triple combination of A...

SAN DIEGO and SUZHOU, China, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Cuong Do, MBA, to Adagene’s board of directors (t...

- Interim phase 1b/2 data report safety profile of ADG116 across dosing levels, with repeat dosing of more than four cycles both as monotherapy and in combination with anti-PD-1 therapy - - Results include two partial responses as monotherapy in Kaposi’s sarcoma and renal...

- NEObody technology platform enables dynamic targeting of a distinct epitope of CTLA-4 for enhanced safety and efficacy - - Data from phase 1b/2 studies in heavily pre-treated patients showcase differentiated safety profile of ADG116 across dosing levels, with repeat dosing both ...

- Best-in-class profile demonstrated with repeat dosing across dose levels - - Antitumor activity observed in cold tumors with steady accumulation of activated ADG126 - - On track in 2022 to report results of ADG126 dose escalation in combination with anti-PD-1 therapy, ...

Adagene ADR press release ( NASDAQ: ADAG ): 1H GAAP EPS of -$0.87 misses by $0.45 . Revenue of $3.93M (+189.0% Y/Y) misses by $9.82M . Financial Outlook of 2023. ADG116 phase 2a proof-of-concept data from combination dose expansion cohorts. ADG126 phase 2a ...

– Topline data for anti-CTLA-4 antibody, ADG116, shows compelling clinical safety and complete and partial responses as both a single agent and in combination with anti-PD-1 therapy; results to be presented at SITC 2022 – – Masked, anti-CTLA-4 antibody,...

Aspen Aerogels ( ASPN ) +42% following its decision to not advance with stock and debt offering. Codex DNA ( DNAY ) +15% . Mullen Automotive ( MULN ) +12% . Adagene ( ADAG ) +7% on $10M share buyback. SoundHound ( SOUN ) +7% ...

Gainers: Adagene ( ADAG ) +20.3 % . Qorvo ( QRVO ) +11.5% . Lexicon Pharmaceuticals ( LXRX ) +9.8% . Avadel Pharmaceuticals ( AVDL ) +9.0% . The RealReal ( REAL ) +7.3% . Losers: HyperFeed Technologies ( HYPR ) ...

Adagene ( NASDAQ: ADAG ) on Wednesday authorized a share buyback of up to $10M of its U.S.-listed shares. The micro-cap company's stock surged ~30% to $2.72 in aftermarket trading. ADAG said it expects to use its existing funds to fund repurchases made under the sh...